

Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders

Julien Rossignol, Amani Ouedrani, Cristina Bulai Livideanu, Stéphane Barete, Louis Terriou, David Launay, Richard Lemal, Celine Greco, Laurent Frenzel, Cecile Meni, et al.

▶ To cite this version:

Julien Rossignol, Amani Ouedrani, Cristina Bulai Livideanu, Stéphane Barete, Louis Terriou, et al.. Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders. Journal of Allergy and Clinical Immunology: In Practice, 2022, 10 (5), pp.1356-1364.e2. 10.1016/j.jaip.2021.12.038. pasteur-03697054

HAL Id: pasteur-03697054 https://pasteur.hal.science/pasteur-03697054v1

Submitted on 22 Jul2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Version of Record: https://www.sciencedirect.com/science/article/pii/S2213219822000150 Manuscript_ec50ad49d15bc5c06a39a2a05d92eccc

Rossignol et al. 1

1 Effective anti-SARS-CoV-2 immune response in patients with clonal mast cell disorders.

2

3	Julien Rossignol ^{1,2*} MD, PhD, Amani Ouedrani ^{3,4*} PhD, Cristina Bulai Livideanu ⁵ MD,
4	Stéphane Barete ⁶ MD, PhD, Louis Terriou ⁷ MD, David Launay ⁷ MD, PhD, Richard Lemal ⁸
5	MD, PhD, Celine Greco ^{1,2} MD, PhD, Laurent Frenzel ^{1,2} MD, PhD, Cecile Meni ¹ MD,
6	Christine Bodemere-Skandalis ^{1,2} MD, PhD, Laura Polivka ^{1,2} MD, PhD, Anne-Florence
7	Collange ^{1,2} , Hassiba Hachichi MSc ¹ , Sonia Bouzourine ¹ , Djazira Nait Messaoud ¹ , Mathilde
8	Negretto ⁵ , Laurence Vendrame ³ , Marguerite Jambou ³ , Marie Gousseff ⁹ MD, Stéphane
9	Durupt ¹⁰ MD, Jean-Christophe Lega ¹⁰ MD, PhD, Jean-Marc Durand ¹¹ MD, PhD, Caroline
10	Gaudy ¹¹ MD, PhD, Gandhi Damaj ¹² MD, PhD, Marie-Pierre Gourin ¹³ MD, Mohamed
11	Hamidou ¹⁴ MD, PhD, Laurence Bouillet ¹⁵ MD, PhD, Edwige Le Mouel ¹⁶ MD, Alexandre
12	Maria ¹⁷ MD, Patricia Zunic ¹⁸ MD, Quentin Cabrera ¹⁸ MD, Denis Vincent ¹⁹ MD, PhD,
13	Christian Lavigne ²⁰ MD, PhD, Etienne Riviere ²¹ MD, Clement Gourguechon ²² MD, Anne
14	Brignier ²³ MD, PhD, Ludovic Lhermitte ²⁴ MD, PhD, Thierry Jo Molina ^{2,25} MD, PhD, Julie
15	Bruneau ^{2,25} MD, PhD, Julie Agopian ²⁶ , Patrice Dubreuil ²⁶ PhD, Dana Ranta ²⁷ MD, Alexandre
16	Mania ⁸ MD, Michel Arock ²⁸ MD, PhD, Isabelle Staropoli ²⁹ PhD, Olivier Tournilhac ⁸ MD,
17	PhD, Olivier Lortholary ^{1,2} MD, PhD, Olivier Schwartz ²⁹ PhD, Lucienne Chatenoud ^{3,4} MD,
18	PhD and Olivier Hermine ^{1,2†} MD, PhD.
19	* <u>Co-authorship</u>
20	[†] <u>Corresponding author</u>
21	Authors' affiliations.
22	¹ French Reference Center for Mastocytosis (CEREMAST), Necker-Enfants Malades
23	University Hospital, AP-HP, Paris, France
24	² Paris University, Imagine Institute, INSERM U1163, Necker-Enfants Malades University
25	Hospital, Paris, France

- ³ Paris University, Necker-Enfants Malades Institute, CNRS UMR 8253 and INSERM
 UMR1151, Necker-Enfants Malades University Hospital, Paris, France
- ⁴ Laboratory of Immunoregulation and Immunopathology, Necker-Enfants Malades
 University Hospital, AP-HP, Paris, France
- ⁵ French Reference Center for Mastocytosis (CEREMAST), Department of Dermatology,
- 31 Hôpital Larrey, Toulouse University Hospital, Toulouse, France
- ⁶ French Reference Center for Mastocytosis (CEREMAST), Department of Dermatology,
- 33 Pitié-Salpêtrière University Hospital, AP-HP, Paris, France
- ⁷ University Lille, INSERM, CHU Lille, Department of Internal Medicine and Clinical
- 35 Immunology, U1286 INFINITE Institute for Translational Research in Inflammation, Lille,
- 36 France
- ⁸ Adult Clinical Hematology, Clermont-Ferrand University Hospital, INSERM CIC501, EA
- 38 7453 -Université Clermont Auvergne, Clermont-Ferrand, France
- ⁹ Department of Internal Medicine, Bretagne Atlantique Hospital, Vannes, France
- 40 ¹⁰ Department of Internal Medicine, Adult Cystic Fibrosis Care Center, Hospices Civils de
- 41 Lyon, Lyon, France
- 42 ¹¹ Department of Internal Medicine, Aix-Marseille University, Timone University Hospital,
- 43 Marseille, France
- ¹² Haematology Institute, Normandy University School of Medicine, Caen, France.
- ¹³ Laboratory of Hematology, Dupuytren University Hospital, Limoges, France
- ¹⁴ Department of Internal Medicine, Hôtel-Dieu University Hospital, Nantes, France
- 47 ¹⁵ Clinical Immunology/Internal Medicine Department, National Reference Center for
- 48 Angioedema, Grenoble University Hospital, Grenoble, France
- 49 ¹⁶ Department of Internal Medicine and Clinical Immunology, Rennes University Hospital,
- 50 Rennes, France

51	¹⁷ Department of Internal Medicine, Montpellier University Hospital, Montpellier, France
52	¹⁸ Department of Haematology, Sud Réunion University Hospital, Saint Pierre, La Réunion,
53	France
54	¹⁹ Department of Pneumology and Internal Medicine, Caremeau University Hospital, Nimes,
55	France
56	²⁰ Department of Internal Medicine, Angers University Hospital, Angers, France
57	²¹ Department of Internal Medicine, Bordeaux University Hospital, Haut-Lévêque Hospital,
58	Pessac, France
59	²² Department of Hematology, Amiens University Hospital, Amiens, France
60	²³ Therapeutic Apheresis Unit, Saint-Louis University Hospital, AP-HP, Paris, France
61	²⁴ Laboratory of Onco-Hematology, Necker-Enfants Malades University Hospital, APHP,
62	Paris, France
63	²⁵ Pathology Department, Necker-Enfants Malades University Hospital, APHP, Paris, France
64	²⁶ CRCM, [Signaling, Hematopoiesis and Mechanism of Oncogenesis, CEREMAST,
65	AFIRMM], INSERM U1068; Institut Paoli-Calmettes; Aix-Marseille Univ, UM105; CNRS,
66	UMR7258, Marseille, F-13009, France
67	²⁷ Department of Haematology, Nancy University Hospital, Nancy, France
68	²⁸ Laboratory of Haematology, Pitié-Salpêtrière University Hospital, Paris, France
69	²⁹ Virus & Immunity Unit, Department of Virology, Institut Pasteur, CNRS UMR3569, Paris,
70	France
71	[†] Corresponding author:
72	Professor Olivier Hermine
73	Service d'hématologie adulte
74	Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades
75	149-161 Rue de Sèvres

76 F-75743 Paris Cedex 15, France

77 E-mail: ohermine@gmail.com

- 78 Phone: +33-144-495-282
- 79

80 Funding sources, Disclosure of Conflicts of Interest for this study:

- 81 All authors declare no conflicts of interest for this work
- 82 Julien Rossignol MD PhD: Consulting fees from Blueprint and Novartis
- 83 Amani Ouedrani PhD: Author has no conflict of interest to declare
- 84 Cristina Bulai Livideanu MD: Author has no conflict of interest to declare
- 85 Stéphane Barete MD PhD: Author has no conflict of interest to declare
- 86 Louis Terriou MD: Author has no conflict of interest to declare
- 87 David Launay MD PhD: Author has no conflict of interest to declare
- 88 Richard Lemal MD PhD: Author has no conflict of interest to declare
- 89 Celine Greco MD PhD: Author has no conflict of interest to declare
- 90 Laurent Frenzel MD PhD: Author has no conflict of interest to declare
- 91 Cecile Meni MD: Author has no conflict of interest to declare
- 92 Christine Bodemere-Skandalis MD PhD: Author has no conflict of interest to declare
- 93 Laura Polivka MD PhD: Author has no conflict of interest to declare
- 94 Anne-Florence Collange: Author has no conflict of interest to declare
- 95 Hassiba Hachichi MSc: Author has no conflict of interest to declare
- 96 Sonia Bouzourine: Author has no conflict of interest to declare
- 97 Djazira Nait Messaoud: Author has no conflict of interest to declare
- 98 Mathilde Negretto: Author has no conflict of interest to declare
- 99 Laurence Vendrame: Author has no conflict of interest to declare
- 100 Marguerite Jambou: Author has no conflict of interest to declare

- 101 Marie Gousseff MD: Author has no conflict of interest to declare
- 102 Stéphane Durupt MD: Author has no conflict of interest to declare
- 103 Jean-Christophe Lega MD PhD: Author has no conflict of interest to declare
- 104 Jean-Marc Durand MD PhD: Author has no conflict of interest to declare
- 105 Caroline Gaudy MD PhD: Consulting fees and/or honoraria from BMS, Blueprint, MSD,
- 106 Roche
- 107 Gandhi Damaj MD PhD: Consulting fees and/or honoraria from Takeda, Iqone, Blueprint
- 108 Marie-Pierre Gourin MD: Author has no conflict of interest to declare
- 109 Mohamed Hamidou MD: Consulting fees from Blueprint
- 110 Laurence Bouillet MD PhD: Research grants, and/or consulting fees, and/or honoraria from
- 111 Takeda, CSL Behring, Biocryst, Biomarin, Novartis, GSK.
- 112 Edwige Le Mouel MD: Author has no conflict of interest to declare
- 113 Alexandre Maria MD: Author has no conflict of interest to declare
- 114 Patricia Zunic MD: Author has no conflict of interest to declare
- 115 Quentin Cabrera MD: Author has no conflict of interest to declare
- 116 Denis Vincent MD PhD: Author has no conflict of interest to declare
- 117 Christian Lavigne MD MSc: Consulting fees and/or honoraria from Sanofi-Genzyme,
- 118 Boehringer-Ingelheim, Shire, Ultragenyx, Biomarin
- 119 Etienne Riviere MD, PhD: Author has no conflict of interest to declare
- 120 Clement Gourguechon MD: Author has no conflict of interest to declare
- 121 Anne Brignier MD PhD: Author has no conflict of interest to declare
- 122 Ludovic Lhermitte MD PhD: Author has no conflict of interest to declare
- 123 Thierry Jo Molina MD PhD: Author has no conflict of interest to declare
- 124 Julie Bruneau MD PhD: Author has no conflict of interest to declare
- 125 Julie Agopian MSc: Author has no conflict of interest to declare

126 Patrice Dubreuil PhD: Author has no conflict of interest to declare

127 Dana Ranta MD: Author has no conflict of interest to declare

128 Alexandre Mania MD: Author has no conflict of interest to declare

129 Michel Arock MD PhD: Consultancy fees from Blueprint et Novartis

130 Isabelle Staropoli PhD: Author has no conflict of interest to declare

131 Olivier Tournilhac MD PhD: Author has no conflict of interest to declare

132 Olivier Lortholary MD PhD: Author has no conflict of interest to declare

133 Olivier Schwartz PhD: Author has no conflict of interest to declare

134 Lucienne Chatenoud MD PhD: Author has no conflict of interest to declare

135 Olivier Hermine MD PhD: AB science: Consultancy, Equity Ownership, Honoraria, Research

136 Funding; Celgene: Research Funding; Novartis: Research Funding.

137

Word counts: Abstract: 247/250 words – Manuscript: 3689/3500 words – Figures: 4 –
Tables: 1 – Supplemental Figure: 3 – Supplemental Table: 1 – References: 26.

140

141 Abstract

Background: Mast cells are key players in innate immunity and the Th2 adaptive immune response. The latter counterbalances the Th1 response, which is critical for antiviral immunity. Clonal mast cell activation disorders (cMCADs, such as mastocytosis and clonal mast cell activation syndrome) are characterized by abnormal mast cell accumulation and/or activation. No data on the antiviral immune response in patients with MCADs have been published.

148 Objective: To study a comprehensive range of outcomes in cMCAD patients with PCR- or 149 serologically confirmed COVID-19 and to characterize the specific anti-SARS-CoV-2 150 immune response in this setting. Methods: Clinical follow-up and outcome data were collected prospectively over a 12-month
period by members of the French *Centre de Référence des Mastocytoses* rare disease network.
Anti-SARS-CoV-2-specific T-cell activity was measured with an enzyme-linked immunospot
assay, and humoral responses were evaluated by assaying circulating levels of specific IgG,
IgA and neutralizing antibodies.

Results: Overall, 32 cMCAD patients were evaluated. None required non-invasive or mechanical ventilation. Two patients were admitted to hospital for oxygen and steroid therapy. The SARS-CoV-2-specific immune response was characterized in 21 of the 32 patients. Most had high counts of circulating SARS-CoV-2-specific, interferon (IFN)- γ producing T-cells and high titers of neutralizing anti-spike IgGs. The patients frequently showed spontaneous T-cell IFN- γ production in the absence of stimulation; this production was correlated with basal circulating tryptase levels (a marker of the mast cell burden).

163 Conclusion: Patients with cMCADs might not be at risk of severe COVID-19 – perhaps due
164 to their spontaneous production of IFN-γ.

165

166 Highlights box:

167 What is already known about this topic?

Mast cells are key players in the Th2 immune response but not in antiviral immune responses.
Data on antiviral responses (and especially responses against coronaviruses) in patients with
clonal mast cell activation disorders have not previously been reported.

171 What does this article add to our knowledge?

In a comprehensive, prospective study, we did not observe any cases of severe COVID-19among groups of patients with clonal mast cell activation disorders. The patients showed

effective anti-coronavirus immune responses. Spontaneous interferon gamma release (in the
absence of T-cell stimulation) was observed frequently in patients with clonal mast cell
activation disorders and was correlated with the basal tryptase level.

177 How does this study impact current management guidelines?

The observed spontaneous production of interferon gamma (correlated with the mast cell burden) suggests that mast cells have a role in the antiviral immune response. The four patients with serial serologic measurements became seronegative over time. Hence, anti-SARS-CoV-2 vaccination after COVID-19 is strongly recommended in patients with clonal mast cell activation disorders.

- 183 Key words: SARS-CoV-2, COVID-19, Mast cells, Mastocytosis, Clonal mast cell activation
- 184 syndrome, Mast cell activation disorders, T-cells, B-cells
- 185

186 Abbreviations

- 187 APHP: Assistance Publique Hôpitaux de Paris (Paris Public Hospital Group)
- 188 BMI: body mass index
- 189 CEREMAST: Centre de Référence des Mastocytoses
- 190 CM: cutaneous mastocytosis
- 191 cMCAD: clonal mast cell activation disorder
- 192 COVID-19: coronavirus disease 19
- 193 HEK: human embryonic kidney
- 194 IFN: interferon
- 195 ISM: indolent systemic mastocytosis
- 196 MIS: mastocytosis in the skin
- 197 MCAS: mast cell activation syndrome
- 198 MMAS: monoclonal mast cell activation syndrome

- 199 NK: natural killer
- 200 PBMC: peripheral blood mononuclear cell
- 201 PHA: phytohemagglutinin
- 202 PMSI: Programme de médicalisation des systèmes d'information
- 203 SARS-CoV-2: severe acute respiratory syndrome coronavirus 2
- 204 SSM: smoldering systemic mastocytosis
- 205 WHO: World Health Organization

206 Introduction

207 Clonal mast cell activation disorders (cMCADs) constitute a heterogeneous disease spectrum 208 that ranges from monoclonal mast cell activation syndrome (MMAS) to mastocytosis and is 209 characterized by the pathological activation and/or accumulation of mast cells (MC)¹. In 210 adults, the most frequent cMCAD is indolent systemic mastocytosis (ISM). Advanced 211 mastocytosis (including aggressive systemic mastocytosis, MC leukemia, and systemic 212 mastocytosis with an associated hematological neoplasm) is rarer and is linked to a poor 213 prognosis^{2.3}.

Coronavirus disease 2019 (COVID-19) is a potentially fatal, pandemic infectious disease caused by severe respiratory syndrome coronavirus 2 (SARS-CoV-2)⁴. A body of compelling pathophysiological data suggests that interferons (IFNs) have a major role in disease control. These includes type I IFN (produced by plasmacytoid dendritic cells) and type III IFN (IFN- γ) produced by T-cells from the adaptive immune system in the early and late phases of the disease, respectively^{5–8}.

One can hypothesize that the MCs' ability to drive Th2 responses^{9–11} (which counterbalance Th1 responses) might impair antiviral immunity in patients with cMCADs. Furthermore, histamine blocks the *in vitro* activity of plasmacytoid dendritic cells; *in vivo*, this might weaken antiviral immune responses¹². MCs might therefore (i) contribute to COVID-19induced inflammation by releasing pro-inflammatory cytokines such as interleukin (IL-)1, IL6, and tumor necrosis factor (TNF) and (ii) exacerbate COVID-19 lung damage *via*degranulation^{13,14}. If so, this would render patients with cMCAD more susceptible to severe
COVID-19.

Over a 12-month period, members of the French *Centre de Référence des Mastocytoses* (CEREMAST) rare disease network collected data prospectively on the patients with cMCADs (MMAS and mastocytosis) and a positive PCR test or serology assay for SARS-CoV-2. Here, we describe the patients' clinical course, outcomes, and immunologic characteristics.

233 Methods

234 Patients

The members of the CEREMAST network collected data prospectively from patients with a 235 cMCAD and COVID-19, as documented by either a positive SARS-CoV-2 PCR test on a 236 nasal swab or symptoms suggestive of COVID-19 and a positive anti-SARS-CoV-2 serology 237 assay. Patients with symptoms suggestive of COVID-19 but who lacked a positive PCR test 238 or a positive serology assay for SARS-CoV-2 infection were excluded from the study. The 239 study data were covered cases recorded between February 1st, 2020, and February 1st, 2021. 240 cMCADs were diagnosed according to the 2016 World Health Organization (WHO) 241 classification^{1,15}. 242

Firstly, we sent a questionnaire to all adult patients (aged 18 or over) with mastocytosis or MMAS and for whom recent follow-up data were available in the CEREMAST national registry (n=828) and who were participating in a study sponsored by the *Association Française pour les Initiatives de Recherche sur le Mastocyte et les Mastocytose* (AFIRMM)

study. The questionnaire was designed to collect data on any signs of MC activation displayed 247 during COVID-19, the patient's treatments, and the patient's specific signs and outcomes 248 related to COVID-19. We then classified the patients as having had proven COVID-19 or not 249 250 (Figure 1). Subsequently, we surveyed all members of the CEREMAST network (n=24) and thereby collected data on patients who had presented with COVID-19 but had not replied to 251 the questionnaire. To check that we had not missed any severe cases (at least in the greater 252 Paris region, as a proxy for national coverage), we also searched the French national hospital 253 254 discharge database (Programme de médicalisation des systèmes d'information, PMSI) for cMCAD patients admitted for COVID-19 to hospitals in the Assistance Publique - Hôpitaux 255 de Paris (the Paris Public Hospital Group, which treats 8.3 million patients a year). All 256 patients with confirmed COVID-19 were assayed for anti-SARS-CoV-2 antibodies. In order 257 to characterize the anti-SARS-CoV-2 immune response, patients included in the AFIRMM 258 259 register were asked to provide a blood sample (for serology testing) during a follow-up consultation. 260

For the experiment on spontaneous IFN- γ production, we incorporated a control group of patients with idiopathic mast cell activation syndrome (MCAS) and who had either experienced mild-to-moderate COVID-19 (n=2) or had no history of COVID-19 (n=9). MCAS was diagnosed according to the modified European Competence Network on Mastocytosis guidelines¹⁶. An increase in the serum total tryptase level by at least 20% above baseline plus 2 ng/mL during or within 4 hours of a symptomatic period was not investigated in the majority of patients.

To measure the spontaneous production of IFN γ in the ELIspot assay, we studied PBMCs from patients with cMCADs and MCAS (with and without a history of COVID-19) and healthy donors with a history of COVID-19.

271 *Ethic Statements*

All the patients with cMCADs were followed up in CEREMAST mastocytosis network 272 reference centers and were enrolled in a prospective, nationwide, multicenter study sponsored 273 by AFIRMM. The AFIRMM study was approved by the local investigational review board 274 (Comité de Protection des Personnes Ile-de-France, France; reference: 93-00) and was 275 carried out in compliance with the principles of the Declaration of Helsinki. The patients gave 276 their written informed consent to participation. The patients' blood samples were obtained as 277 part of routine follow-up care for their cMCADs. Data on the control cohorts were collected 278 279 prospectively and analyzed as part of the COVID-HOP study (Clinicaltrials.gov: NCT04418375; other study identifier: APHP200609). 280

281 Immunological assays

SARS-CoV-2 specific T-cell responses were evaluated by measuring the cells' IFN-y 282 production in an enzyme-linked immunospot (ELISpot) assay. Briefly, peripheral blood 283 mononuclear cells (PBMCs) were isolated from fresh blood collected during a follow-up 284 consultation. After isolation on a Ficoll density gradient, the PBMCs were stimulated for 18 285 to 20 h with individual 15-mer 11-aa overlapping peptide pools for various SARS-CoV-2 286 proteins or common coronavirus proteins. Each responding cell generated a spot. The 287 ELISpot results were expressed as the number of spot-forming cell (SFCs)/10⁶ CD3⁺ T-cells 288 after the subtraction of background values from wells with non-stimulated cells. 289

The negative controls were PBMCs cultured in RPMI-1640 medium supplemented with Lglutamine, sodium bicarbonate (Sigma-Aldrich, Molsheim, France) and 10% human AB serum (Biowest, Nuaillé, France), in the absence of stimulation. The positive controls were phytohemagglutinin (PHA) (Sigma-Aldrich) and the CEFX Ultra SuperStim Pool (JPT Peptide Technologies GmbH, BioNTech AG, Berlin, Germany). The tested SARS-CoV-2 peptide pools were derived from a peptide scan through the SARS-CoV-2 spike glycoprotein (two pools: S1 for the N-terminal fragment, and S2 for the C-terminal fragment), membrane
protein (M), nucleoprotein (N), envelope small membrane protein (E), and ORF3a protein.
We also tested peptide pools derived from the spike glycoprotein of the common human
alpha-coronaviruses (HCoV-229E and HCoV-NL63) and beta-coronaviruses (HCoV-OC43
and HCoV-HKU1).

301 The humoral immune response (including the production of anti-spike SARS-CoV-2 IgG, IgA antibodies and the neutralizing ability of anti-spike IgGs) was characterized using previously 302 described S-flow and S-pseudotype neutralization assays¹⁷. Briefly, the S-flow assay used 303 human embryonic kidney (HEK)293T cells transduced with the SARS-CoV-2 spike protein. 304 Cells were incubated with sera from patients (dilution: 1:300) and stained with either anti-IgG 305 306 or anti-IgA antibodies. The fluorescent signal was measured by flow cytometry. For the Spseudotype neutralization assay, pseudotyped viruses carrying SARS-CoV-2 spike protein 307 were used. The viral pseudotypes were incubated with the sera to be tested (dilution: 1:100), 308 309 added to transduced HEK293T cells expressing ACE2, and incubated for 48 h at 37°C. The assay measures the anti-S antibodies' ability to neutralize an infection, as described 310 elsewhere¹⁷. 311

312 Non-cMCAD control groups

For each group, the number of patients, the median age and the sex ratio are reported in Supplemental Table E1. Four control groups were used in this study: (i) non-MCAD patients convalescing from mild-to-moderate (n=17) and (ii) severe (n=15) forms of COVID-19 and who had already been evaluated with SARS-CoV-2 ELISpot and serology assays in Necker Hospital's immunology laboratory, (iii) idiopathic MCAS patients with or without a history of COVID-19, and (iv) non-MCAD patients with no history of COVID-19 (n=15). We compared the cMCAD patients with age-matched MCAS patients who presented symptoms of MC activation and were being treated with antimediator agents; at the time of the SARS-CoV-2 infection and the immunoassays, all 11 of the MCAS patients were being treated with H1 antihistamines, 8 were being treated with H2 antihistamines, and 5 were being treated with montelukast. The cMCAD and MCAS patient subgroups did not differ significantly with regard to age (mean age: 45.6 vs. 49.2, respectively; p=0.35).

325 *Statistics*

Statistical analyses were performed using GraphPad Prism software (version 6.0; GraphPad
Software, Inc., La Jolla, CA). Groups were compared using Student's t test, a chi-square test
or Fisher's exact test, as appropriate. Data were expressed as the mean, median [interquartile
range], or median (range). The threshold for statistical significance was set to p<0.05 (*,
p<0.05; **, p<0.01; ***, p<0.001, ****, p<0.0001, in figure legends).

331

332 **Results**

From February 1st, 2020, to February 1st, 2021, 32 patients with cMCADs and proven COVID-19 were prospectively identified by the CEREMAST network (Figure 1). Eighteen of the 32 had replied to the questionnaire, and 14 patients had been subsequently identified by referring physicians in CEREMAST centers. No additional inpatient cases were found in the APHP database.

The characteristics and outcomes of the 32 patients with cMCADs and COVID-19 are summarized in Table 1. The median (range) age was 49.7 years (range: 25.6–76.4), with female predominance (59.4%). The cMCAD subtype was cutaneous mastocytosis or mastocytosis in the skin in 14 patients, ISM in 15 patients, smoldering systemic mastocytosis (SSM) in one patient, and MMAS in 2 patients. Of the 21 patients having undergone genetic

testing, 18 (85.7%) carried the D816V KIT mutation. Ten patients (31.3%) had experienced a 343 severe anaphylactic reaction, and the median (range) basal serum tryptase level before the 344 appearance of clinical or laboratory signs of COVID-19 was 13.0 µg/L (2.7–163.0 µg/L). 345 Risk factors for severe COVID-19 were present in 13 of the 32 patients (40.6%), and four had 346 at least two risk factors¹⁸: a body mass index >30 (n=4), age >65 (n= 4), ongoing 347 cytoreductive therapy (midostaurin or cladribine) or recent (in the previous 12 months) 348 administration of cladribine (n=3), cardiovascular conditions (including arterial hypertension 349 350 and chronic heart failure) (n=7), and diabetes (n=2). At the time of the SARS-CoV-2 infection, 23 of the 32 patients (71.9%) were taking symptomatic medications (H1 351 antihistamines, H2 antihistamines, and/or montelukast), one patient with SSM was receiving 352 midostaurin after failure to respond to cladribine, and one patient with ISM had recently 353 received cladribine. 354

With regard to the diagnosis of COVID-19, 23 of the 32 patients (71.9%) had a positive 355 356 SARS-CoV-2 PCR test on a nasal swab, and 9 of the 32 had a negative PCR test (or did not undergo a PCR test on a nasal swab, due to non-availability of the procedure at the time of 357 infection) and positive serology test. The great majority of the patients (29 out of 32) became 358 seropositive during their follow-up. As expected, patients with subsequently available serum 359 samples (n=4) became seronegative after a median follow-up of 33.0 weeks. Regarding the 360 symptoms of COVID-19, 22 of the 32 (68.8%) patients had fever (>38°C), and 18 (56.3%) 361 had anosmia and/or ageusia. Only two patients were admitted to hospital for corticosteroid 362 therapy and oxygen therapy (corresponding to stage 5 on the WHO COVID-19 clinical 363 progression scale¹⁹) but neither required non-invasive or mechanical ventilation. Interestingly, 364 8 of the 32 patients (25.0%) reported an increase in signs of MC activation during the episode 365 of COVID-19, while 3 (9.4%) reported a decrease. No recurrences of the infection were 366 367 reported.

The specific cellular and humoral anti-SARS-CoV-2 immune responses were studied in 21 368 patients with cMCADs a median [IQR] of 24 weeks [7–36] from infection. Overall, 20 of the 369 21 cMCAD patients developed a specific T-cell response against at least one of the SARS-370 CoV-2 peptide pools tested. The responses were usually moderately intense. The median 371 [IQR] intensity was 37 [24–130] SFC/10³ CD3 for the S1 pool, 108 [23–201] SFC/10³ CD3 372 for the S2 pool, 62 [21–146] SFC/10³ CD3 for the M pool, 78 [48–256] SFC/10³ CD3 for the 373 N pool and 23 [10–66] SFC/10³ CD3 for the AP3a pool. The only patient (#6) who did not 374 develop a specific T-cell response was young (38), had presented mild symptoms of COVID-375 19 (confirmed by a positive PCR test on a nasal swab), and did not have a history of 376 immunodeficiency or immunosuppressive therapy. 377

Interestingly, the frequencies and intensities of the S2, M, N and AP3a pool responses 378 379 observed for cMCAD patients were similar to those observed for the control group of patients with mild-moderate COVID-19 (n=17) (Figure 2). However, the median [IQR] response for 380 381 the spike glycoprotein N-terminal fragment pool was significantly lower for the patients with cMCADs (37 [24–130] SFC/10³ CD3) than for the mild-to-moderate COVID-19 controls 382 (114 [52–289] SFC/10³ CD3; p=0.0288). The SARS-CoV-2 specific T-cell responses were 383 significantly lower for cMCAD patients (p<0.001) than in severe COVID-19 controls (n=15), 384 with the exception of the N pool (Figure 2). It is noteworthy that we did not detect (or 385 detected very few) specific T-cell responses to the SARS-CoV-2 envelope small membrane 386 protein in any of the groups. The anti-SARS-CoV-2 immune profiles of patient #20 (grade 5 387 on the WHO COVID-19 clinical progression scale) and patient #30 (who had recently been 388 given cladribine) did not appear to differ from those observed in the other patients. 389

To evaluate the overall anticoronavirus immune response in 18 patients with cMCADs, we studied T-cell specific responses against the spike glycoprotein of human alpha- and betacoronaviruses HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1. Two peptide

pools (S1 and S2) were tested, as had been done for the SARS-CoV-2 spike glycoprotein 393 (Supplemental figure E1). The samples from cMCAD patients and non-cMCAD controls gave 394 very similar responses. We did not evidence any defects in the anti-endemic coronavirus 395 response in patients with cMCADs; the frequencies and intensities were similar to those 396 observed for non-cMCAD controls. The same was true when comparing IFN-y production 397 responses to the ELISpot positive control CEFX Ultra SuperStim Pool (containing 176 known 398 peptide epitopes derived from a broad range of infectious agents) in cMCAD vs. non-cMCAD 399 patients (Supplemental figure E2). 400

In parallel with the ELISpot assay, we also used a high-sensitivity assay (the S-flow assay) to 401 study SARS-CoV-2-specific IgG and IgA in 15 cMCAD patients. Fourteen of the 15 patients 402 403 were positive for IgG, and 7 of the 15 were positive for IgA. The IgG-negative patient (#6) had a negative ELISpot assay. Furthermore, we used a viral pseudoparticle neutralization 404 assay to determine whether the SARS-CoV-2-specific IgGs were neutralizing. We detected 405 406 neutralizing antibodies in 12 of the 14 IgG-seropositive patients (86%) and found that anti-SARS-CoV-2 seropositivity (the IgG titer) was associated with a high level of neutralizing 407 antibody (Supplemental figure E3). 408

Interestingly, inspection of the ELISpot plates showed that the background signal was significantly higher in cMCAD wells than in non-cMCAD control wells. In wells containing non-stimulated PBMCs in culture medium but with no peptide pools, we counted more than 10 small spots per $2x10^5$ CD3+ cells in 10 of the 24 cMCAD patients (with or without a history of COVID-19), 3 of the 31 non-cMCAD controls (p=0.009 in Fisher's exact test), and 2 of the 11 controls with idiopathic MCAS (Figure 3A).

It should be noted that the SARS-CoV-2-specific spots were much larger and more intense than the background spots (Figure 3B-E). Thus, adjustment the ELISpot reader's settings made it possible to count the SARS-CoV-2-specific spots accurately and objectively. This

phenomenon resulted from spontaneous IFN- γ release in the absence of stimulation. Given 418 that we had tested the total PBMC fraction, we were not able to identify the specific subset of 419 IFN-y producing cells. PBMCs include T-cells, B-cells, natural killer (NK) cells, monocytes, 420 and other myeloid cells (such as dendritic cells). Spontaneous IFN-y release can be associated 421 with elevated levels of basal T-cell activation. In a study of HIV-1-seronegative people, Liu et 422 al.²⁰ reported that the frequency of activated CD4+ T-cells (CD4+CD38+HLA-DR+) and 423 CD8+ T-cells (CD8+CD38+HLA-DR+) was greater in individuals with a high background 424 than in individuals with a low background. Another hypothesis involves NK cells, which 425 might contribute to the maintenance of an elevated baseline IFN- γ level. It has been reported 426 that NK cells from polyallergic patients spontaneously released greater amounts of IFN-y, IL-427 4, IL-5 and IL-13 than NK cells from healthy individuals did^{21} – highlighting the *in vivo* 428 activation of NK cells in atopic patients and suggesting that NK cells might be involved in an 429 430 unbalanced cytokine network in allergic inflammation.

Accordingly, we sought to determine whether the spontaneous release of IFN- γ by PBMCs 431 432 from cMCAD patients was related to NK cell activity, as has been reported for polyallergic patients. Human NK cells can be divided into NK1 and NK2 subsets on the basis of their 433 ability to secrete IFN- γ^{22} . NK1 secrete IFN- γ and inhibits IgE synthesis in allergy²¹. Levels of 434 total IgE might therefore constitute an indirect marker of NK1 activation. Thus, we 435 determined the total IgE titer in sera from 17 patients with cMCADs. The cohort's total IgE 436 levels were generally low (median [IQR]: 20 IU/ml [IQR 12.8 - 36.5], and were not 437 correlated with spontaneous IFN- γ release. Lastly, we sought to determine whether the 438 spontaneous IFN- γ release was correlated with the patients' characteristics. Although there 439 was no correlation between spontaneous IFN- γ release and age, current symptomatic 440 medications, a history of anaphylaxis, or the presence of the KIT D816V mutation, the basal 441

serum tryptase level was indeed correlated in patients with cutaneous mastocytosis, MIS, or ISM (Figure 4, $r^2=0.61$, p=0.0004).

444

445 **Discussion**

To the best of our knowledge, the present study is the first to have investigated the antiviral 446 immune response in patients with cMCADs. Given that MCs are key players in the Th2 447 immune response, one could reasonably fear that patients with cMCADs might produce 448 449 abnormally poor immune responses to infections by viruses like SARS-CoV-2. To address this hypothesis, we studied a comprehensive range of responses and outcomes in cMCAD 450 patients having developed PCR- or serology-confirmed COVID-19 during a 12-month period 451 in France. Overall, no cases of severe COVID-19 were observed in this comprehensive series 452 of patients – despite the high prevalence of risk factors (obesity, advanced age, cardiovascular 453 conditions, immunosuppressive treatments, etc.). Strikingly, only two patients (with one and 454 three risk factors, respectively) had to be hospitalized for low-flow oxygen therapy, and the 455 outcomes were favorable in both cases. These findings are in line with recently published data 456 from an international study²³. However, the present study extends our knowledge of cMCADs 457 and COVID-19 because of the exhaustive nature of our inclusion process for patients with 458 cMCADs through the nationwide CEREMAST rare disease network. Indeed, whenever a 459 patient with mastocytosis not referenced in the CEREMAST network was hospitalized for the 460 treatment of COVID-19 in an intensive care unit, the local and national reference centers were 461 systematically contacted for an expert opinion on potential drug contraindications (due to the 462 mandatory precautions needed for anesthesia). The exhaustive recruitment of patients with 463 cMCADs and severe or life-threatening COVID-19 was confirmed by consulting PMSI 464 hospital discharge records for the greater Paris region; we did not retrieve any inpatients who 465

had not been detected through the CEREMAST network. For obvious reasons, the only source
of study bias was related to patients with asymptomatic, mild or moderate forms of COVID19 who did not require hospitalization nor request advice from their referring physicians.

To characterize the antiviral immune responses in patients with cMCADs, we have investigated, using ELISpot assay, the T-cells specific responses against SARS-CoV-2, endemic coronavirus and the CEFX Ultra SuperStim Pool containing 176 known peptide epitopes derived from a broad range infectious agent. Furthermore, we studied the specific humoral anti-SARS-CoV-2 response by assaying circulating levels of specific IgG and IgA antibodies and neutralizing antibodies.

We observed that patients with cMCADs and non-cMCAD controls with a history of mild or 475 476 moderate COVID-19 had very similar T-cell profiles in response to SARS-CoV-2, endemic coronaviruses, and the CEFX Ultra SuperStim Pool. Considering these observations as a 477 whole and in contrast to initial expectations, we believe that patients with mastocytosis were 478 479 indeed able to develop an effective, protective Th1 cell response against SARS-CoV-2. Thus, MCs from patients with cMCADs do not appear to worsen the Th1 response. However, given 480 that less intense responses against SARS-CoV-2 spike glycoprotein were observed in cMCAD 481 patients, we cannot rule out an impact of MCs on the amplitude of the Th1 response; this 482 would raise concerns about the post-immunization cellular response. Furthermore, recent 483 research has shown that MCs are involved in the Th1 response in general and the Th1 484 response to viruses in particular^{24–26}. MCs might have a role in the Th1/Th2 balance that is 485 potentially important for preventing the development of severe forms of COVID-19. 486

487 Unexpectedly, our ELISpot assay results revealed that spontaneous IFN- γ release from 488 PBMCs (i.e. release in the absence of any stimulation) was more frequent in cMCAD patients 489 than in controls. We found that spontaneous IFN- γ release was positively correlated with the 490 cMCAD patients' basal tryptase levels; this was the only correlated clinical and laboratory

characteristic, in fact. Although tryptase is very unlikely to be directly involved in this 491 492 phenotype (especially since patients with advanced mastocytosis have very high tryptase levels and are not known to be especially protected against infection), we believe that the 493 clonal MC burden is linked to IFN-y release in patients with non-advanced mastocytosis. To 494 the best of our knowledge, this finding has not previously been reported in the literature and 495 may suggest a degree of additional protection against severe viral diseases. Our laboratory is 496 now working to determine whether this observation is related to either a specific cytokine 497 profile in a patient's plasma or a direct cellular interaction between MCs and T-cells. If 498 confirmed, this specific phenotype in cMCAD patients might lead to therapeutic implications 499 500 in the field of infectious diseases.

501 Overall, our results showed that patients with cMCADs were able to develop effective, 502 protective cellular and humoral responses to SARS-CoV-2. However, all four of the evaluable 503 patients with serial serology data had become seronegative after a median of 33.0 weeks. 504 Thus, anti-SARS-CoV-2 vaccination is strongly recommended in this specific patient 505 population, although its level of effectiveness remains to be characterized.

In conclusion, non-advanced mastocytosis and MMAS appear not to confer an elevated risk of severe COVID-19 on patients. This finding might be due to the spontaneous IFN- γ production observed in patients with cMCADs but must be confirmed by further clinical and laboratory studies. If confirmed, this specific immune profile might explain the observed protection against severe COVID-19.

511

512 Acknowledgements

513 We thank all the patients who filled out the questionnaire and the healthcare professional who 514 cared for the patients with COVID-19.

515 **References**

516	1.	Valent P, Akin C, Metcalfe DD. Review Article Mastocytosis : 2016 updated WHO
517		classi fi cation and novel emerging treatment concepts. Blood. 2017;129:1420-8.
518	2.	Lim K, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, et al. Systemic
519		mastocytosis in 342 consecutive adults : survival studies and prognostic factors
520		Systemic mastocytosis in 342 consecutive adults : survival studies and prognostic
521		factors. 2009;113:5727-36.
522	3.	Gotlib J, Pardanani A, Akin C, Reiter A, George T, Hermine O, et al. International
523		Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
524		& European Competence Network on Mastocytosis (ECNM) consensus response
525		criteria in advanced systemic mastocytosis. Blood. 2013;121:2393-401.
526	4.	Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19
527		Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology,
528		Diagnosis, Treatment, and Control. J Clin Med [Internet]. 2020;9. Available from:
529		http://www.ncbi.nlm.nih.gov/pubmed/32344679
530	5.	Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I
531		interferon activity and inflammatory responses in severe COVID-19 patients. Science
532		[Internet]. 2020;369:718–24. Available from:
533		http://www.ncbi.nlm.nih.gov/pubmed/32661059
534	6.	Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H-H, Zhang Y, et al.
535		Autoantibodies against type I IFNs in patients with life-threatening COVID-19.
536		Science [Internet]. 2020;370. Available from:
537		http://www.ncbi.nlm.nih.gov/pubmed/32972996

538	7.	Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nat Rev
539		Immunol [Internet]. 2020;20:529–36. Available from:
540		http://dx.doi.org/10.1038/s41577-020-0402-6
541	8.	Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al.
542		Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19
543		Disease and Unexposed Individuals. Cell [Internet]. 2020;1–13. Available from:
544		https://doi.org/10.1016/j.cell.2020.05.015
545	9.	van der Ploeg EK, Hermans MAW, van der Velden VHJ, Dik WA, van Daele PLA,
546		Stadhouders R. Increased group 2 innate lymphoid cells in peripheral blood of adults
547		with mastocytosis. J Allergy Clin Immunol [Internet]. 2021;147:1490-1496.e2.
548		Available from: http://www.ncbi.nlm.nih.gov/pubmed/33091410
549	10.	Mazzoni A, Siraganian RP, Leifer CA, Segal DM. Dendritic cell modulation by mast
550		cells controls the Th1/Th2 balance in responding T cells. J Immunol [Internet].
551		2006;177:3577-81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16951316
552	11.	Bulfone-Paus S, Bahri R. Mast cells as regulators of T cell responses. Front Immunol.
553		2015;6:6–11.
554	12.	Smith N, Pietrancosta N, Davidson S, Dutrieux J, Chauveau L, Cutolo P, et al. Natural
555		amines inhibit activation of human plasmacytoid dendritic cells through CXCR4
556		engagement. Nat Commun [Internet]. 2017;8:14253. Available from:
557		http://www.ncbi.nlm.nih.gov/pubmed/28181493
558	13.	Hu Y, Jin Y, Han D, Zhang G, Cao S, Xie J, et al. Mast cell-induced lung injury in
559		mice infected with H5N1 influenza virus. J Virol [Internet]. 2012;86:3347-56.
560		Available from: http://www.ncbi.nlm.nih.gov/pubmed/22238293

561	14.	Kritas SK, Ronconi G, Caraffa A, Gallenga CE, Ross R, Conti P. Mast cells contribute
562		to coronavirus-induced inflammation: new anti-inflammatory strategy. J Biol Regul
563		Homeost Agents [Internet]. 2020;34:9-14. Available from:
564		http://www.ncbi.nlm.nih.gov/pubmed/32013309
565	15.	Valent P, Akin C, Bonadonna P, Hartmann K, Brockow K, Niedoszytko M, et al.
566		Proposed Diagnostic Algorithm for Patients With Suspected Mast Cell Activation
567		Syndrome. J Allergy Clin Immunol Pract [Internet]. 2019;1–10. Available from:
568		https://doi.org/10.1016/j.jaip.2019.01.006
569	16.	Gülen T, Akin C, Bonadonna P, Siebenhaar F, Broesby-Olsen S, Brockow K, et al.
570		Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation
571		Syndromes: A Critical Review. J allergy Clin Immunol Pract [Internet]. 2021;
572		Available from: http://www.ncbi.nlm.nih.gov/pubmed/34166845
573	17.	Grzelak L, Temmam S, Planchais C, Demeret C, Tondeur L, Huon C, et al. A
574		comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in
575		human serum samples from different populations. Sci Transl Med [Internet]. 2020;12.
576		Available from: http://www.ncbi.nlm.nih.gov/pubmed/32817357
577	18.	Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors
578		associated with COVID-19-related death using OpenSAFELY. Nature [Internet].
579		2020;584:430-6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32640463
580	19.	WHO Working Group on the Clinical Characterisation and Management of COVID-19
581		infection. A minimal common outcome measure set for COVID-19 clinical research.
582		Lancet Infect Dis [Internet]. 2020;20:e192–7. Available from:
583		http://www.ncbi.nlm.nih.gov/pubmed/32539990

- 584 20. Liu AY, De Rosa SC, Guthrie BL, Choi RY, Kerubo-Bosire R, Richardson BA, et al.
- 585 High background in ELISpot assays is associated with elevated levels of immune
- 586 activation in HIV-1-seronegative individuals in Nairobi. Immunity, Inflamm Dis
- 587 [Internet]. 2018;6:392–401. Available from:
- 588 http://www.ncbi.nlm.nih.gov/pubmed/29974672
- 589 21. Aktas E, Akdis M, Bilgic S, Disch R, Falk CS, Blaser K, et al. Different natural killer
- 590 (NK) receptor expression and immunoglobulin E (IgE) regulation by NK1 and NK2
- cells. Clin Exp Immunol [Internet]. 2005;140:301–9. Available from:
- 592 http://www.ncbi.nlm.nih.gov/pubmed/15807855
- 593 22. Deniz G, Akdis M, Aktas E, Blaser K, Akdis CA. Human NK1 and NK2 subsets
- 594determined by purification of IFN-gamma-secreting and IFN-gamma-nonsecreting NK
- cells. Eur J Immunol [Internet]. 2002;32:879–84. Available from:
- 596 http://www.ncbi.nlm.nih.gov/pubmed/11870632
- 597 23. Giannetti MP, Weller E, Alvarez-Twose I, Torrado I, Bonadonna P, Zanotti R, et al.
- 598 COVID-19 infection in patients with mast cell disorders including mastocytosis does
- not impact mast cell activation symptoms. J allergy Clin Immunol Pract [Internet].
- 600 2021; Available from: http://www.ncbi.nlm.nih.gov/pubmed/33631409
- 601 24. McAlpine SM, Issekutz TB, Marshall JS. Virus stimulation of human mast cells results
- in the recruitment of CD56 + T cells by a mechanism dependent on CCR5 ligands.
- FASEB J [Internet]. 2012;26:1280–9. Available from:
- 604 https://onlinelibrary.wiley.com/doi/abs/10.1096/fj.11-188979
- 605 25. Ebert S, Becker M, Lemmermann NAW, Büttner JK, Michel A, Taube C, et al. Mast
- 606 Cells Expedite Control of Pulmonary Murine Cytomegalovirus Infection by Enhancing
- 607 the Recruitment of Protective CD8 T Cells to the Lungs. Akbari O, editor. PLoS

608 Pathog [Internet]. 2014;10:e1004100. Available from:

- 609 https://dx.plos.org/10.1371/journal.ppat.1004100
- 610 26. Becker M, Lemmermann NA, Ebert S, Baars P, Renzaho A, Podlech J, et al. Mast cells
- 611 as rapid innate sensors of cytomegalovirus by TLR3/TRIF signaling-dependent and -
- 612 independent mechanisms. Cell Mol Immunol [Internet]. 2015;12:192–201. Available
- 613 from: http://www.nature.com/articles/cmi201473

# Sex	Ag	ge BMI	cMCADs	<i>KIT</i> mutation	History of severe anaphylaxis	Risk factors	Tryptase μg/L	Treatment: anti-H1	Treatment: anti-H2	Treatment: montelukast	Cytoreductive therapy	COVID-19 scale	cMCAD symptoms during COVID-19	Fever during COVID-19	Anosmia/ ageusia during COVID-19	SARS-CoV-2 PCR test	SARS-CoV-2 serology
1 F	25		ISM	WT	no	no	3.9	no	yes	no	no	2	no change	yes	yes	yes	positive
2 F	26		CM	D816V	no	no	4.4	yes	no	yes	no	2	more severe	yes	yes	yes	negative
3 F	29.		MIS	NA	no	no	4.7	no	no	no	no	2	no change	no	no	no	positive
4 F	33.	.4 28.1	CM	D816V	yes	no	6.6	yes	no	no	no	2	no change	yes	yes	no	positive
5 F	35.	.5 33.1	MIS	NA	no	yes	7.4	no	no	no	no	2	no change	no	yes	yes	positive
6 F	38	.3 18.4	ISM	D816V	yes	no	7.0	no	no	no	no	2	more severe	no	no	yes	negative
7 F	40	.3 21.0	CM	WT	no	no	8.1	yes	no	no	no	2	no change	no	yes	no	positive
8 F	41	.4 22.5	ISM	NA	no	no	7.7	yes	no	no	no	2	less severe	yes	yes	yes	positive
9 F	42	.3 20.0	MMAS	D816V	yes	no	18.5	yes	no	yes	no	2	more severe	no	yes	yes	positive
10 M	42	.4 33.5	ISM	D816V	no	yes	2.7	yes	no	no	no	2	less severe	yes	yes	yes	positive
11 F	43	.3 25.0	CM	WT	yes	no	13.0	yes	no	yes	no	2	no change	yes	no	yes	positive
12 F	43	.3 24.3	ISM	D816V	yes	yes	60.0	yes	yes	no	yes	2	more severe	yes	yes	yes	positive
13 F	43	.8 25.1	MIS	NA	no	no	13.0	no	no	no	no	2	no change	yes	yes	yes	positive
14 M	45	.3 30.8	MMAS	D816V	yes	yes	45.0	yes	no	no	no	2	no change	yes	no	no	positive
15 F	48	.1 17.6	ISM	D816V	yes	no	99.8	yes	no	yes	no	2	no change	no	yes	yes	positive
16 M	49	.1 27.4	ISM	D816V	no	no	14.8	yes	yes	no	no	2	more severe	yes	yes	no	positive
17 M	50	.3 23.2	MIS	NA	no	no	18.6	yes	no	no	no	2	no change	no	no	yes	positive
18 M	51	.7 26.4	ISM	D816V	no	no	42.8	yes	no	no	no	2	no change	yes	yes	yes	positive
19 F	52	.2 19.5	ISM	NA	no	no	7.9	yes	no	yes	no	2	no change	yes	no	no	positive
20 F	52	.4 30.1	CM	D816V	no	yes	37.2	yes	no	no	no	5*	more severe	yes	no	yes	positive
21 F	52	.9 17.5	ISM	D816V	no	yes	38.6	yes	no	no	no	2	no change	yes	yes	yes	negative
22 F	53	.1 27.0	MIS	NA	no	no	31.4	no	no	no	no	2	no change	yes	yes	yes	positive
23 M	56	.0 26.8	ISM	NA	no	yes	19.0	no	no	no	no	2	no change	yes	yes	no	positive
24 F	59	.6 21.6	MIS	NA	no	no	56.0	no	no	no	no	2	more severe	no	no	yes	positive
25 M	60	.7 26.6	СМ	D816V	no	no	12.0	no	no	no	no	1	no change	no	no	yes	positive
26 M	62	.2 26.5	ISM	D816V	no	yes	6.1	yes	no	no	no	2	no change	yes	no	no	positive
27 M	62	.2 24.2	CM	D816V	no	no	18.6	yes	no	no	no	2	no change	yes	yes	yes	positive
28 M	63	.2 28.1	MIS	NA	yes	yes	11.2	yes	no	yes	no	2	no change	no	yes	yes	positive
29 M	65	.6 26.7	ISM	D816V	yes	yes	27.8	no	no	no	no	5*	no change	yes	no	yes	positive
30 F	73	.9 21.2	SSM	D816V	no	yes	163.0	no	yes	no	yes	2	no change	yes	no	no	positive
31 M	76	.2 25.4	ISM	D816V	yes	yes	8.5	yes	no	no	no	3	less severe	yes	no	yes	positive
32 M	76	.5 27.8	ISM	NA	no	yes	7.6	no	yes	no	no	2	more severe	yes	no	yes	positive

Table 1: Characteristics of patients with cMCADs and COVID-19 and their outcomes. Patients are listed in order of increasing age (years). #:patient number. F: female. M: male. BMI: body mass index. MIS: mastocytosis in the skin. CM: cutaneous mastocytosis. MMAS: monoclonalmast cell activation syndrome. SSM: smoldering systemic mastocytosis. risk factors: risk factors for severe COVID-19¹⁸. NA: not available.Cytoreductive therapy: midostaurin or ongoing/recent (previous 12 months) administration of cladribine. COVID-19 scale: WHO COVID-19clinicalprogressionscale¹⁹.*Patientstreatedwithcorticosteroids.

Figure legends

Figure 1: Flowchart for the selection of patients with cMCADs and proven COVID-19. cMCAD: clonal mast cell activation disorder.

Figure 2: Quantification of specific anti-SARS-CoV-2 T-cell responses, using an ELISpot assay.

The tested SARS-CoV-2 peptide pools were derived from a peptide scan through the SARS-CoV-2 spike glycoprotein (S1: N-terminal fragment, S2: C-terminal fragment), membrane protein (M), nucleoprotein (N), and ORF3a protein (AP3a). The negative controls were PBMCs in culture medium alone, and the positive controls were PHA and the CEFX Ultra SuperStim Pool. Results were expressed as the number of spot-forming cells (SFCs)/10⁶ CD3+ T-cells after subtraction of the background values from wells with non-stimulated cells. All differences between the non-COVID-19 and COVID-19 groups were statistically significant (p<0.001). cMCADs: convalescent patients with clonal mast cell activation disorders. Non-cMCAD m-m COVID-19: non-cMCAD control patients convalescing from a mild-to-moderate form of COVID-19 (n=17). Non-cMCADs severe COVID-19: non-cMCAD non-COVID-19: non-cMCAD, non-COVID-19 controls (n=15). ns: non-significant; *, p<0.05; ****, p<0.0001.

Figure 3: Spontaneous IFN- γ production by PBMCs from patients, as measured in an ELISpot assay.

Graphic representation of the ELISpot assays A. cMCADs: patients with clonal mast cell activation disorders. Non-cMCAD control groups: MCAS: patients with idiopathic mast cell

activation syndrome; CTR: non-cMCAD/non-MCAS control patients convalescing from COVID-19 (n=32). Empty circles: no history of COVID-19. Filled circles: history of COVID-19. **Pictures of ELISpot assays. B:** A well with non-stimulated PBMCs from a COVID-19 non-cMCAD control. **C**: A well with non-stimulated PBMCs from a COVID-19 cMCAD patient. **D**: A well with PBMCs from a COVID-19 non-cMCAD control after stimulation for 18-20 h with individual 15-mer 11-aa overlapping peptide pools derived from the SARS-CoV-2 N-terminal fragment spike protein. **E**: A well with PBMCs from a COVID-19 cMCAD patient after stimulation with individual 15-mer 11-aa overlapping peptide pools derived pools derived from the SARS-CoV-2 N-terminal fragment spike protein.

Figure 4: Correlation between basal tryptase level (μ g/L) and spontaneous IFN- γ production (spot-forming cells (SFCs)/2x10⁵ CD3), as observed in ELISpot assays. n=24 patients with CM, MIS and ISM. Linear regression: r²=0.44 (p<0.0004).




Figure 1: Flowchart for the selection of patients with cMCADs and proven COVID-19.

cMCAD: clonal mast cell activation disorder.




Figure 2: Quantification of specific anti-SARS-CoV-2 T-cell responses, using an ELISpot assay.

The tested SARS-CoV-2 peptide pools were derived from a peptide scan through the SARS-CoV-2 spike glycoprotein (S1: N-terminal fragment, S2: C-terminal fragment), membrane protein (M), nucleoprotein (N), and ORF3a protein (AP3a). The negative controls were PBMCs in culture medium alone, and the positive controls were PHA and the CEFX Ultra SuperStim Pool. Results were expressed as the number of spot-forming cells (SFCs)/10⁶ CD3+ T-cells after subtraction of the background values from wells with non-stimulated cells. All differences between the non-COVID-19 and COVID-19 groups were statistically significant (p<0.001). cMCADs: convalescent patients with clonal mast cell activation disorders. Non-cMCAD m-m COVID-19: non-cMCAD control patients convalescing from a mild-to-moderate form of COVID-19 (n=17). Non-cMCADs severe COVID-19: non-cMCAD control patients convalescing from a severe form of COVID-19 (n=15). Non-cMCAD non-COVID-19: non-cMCAD non-COVID-19: non-cMCAD (n=15). ns: non-significant; *, p<0.05; ****, p<0.0001.




Figure 3: Spontaneous IFN- γ production by PBMCs from patients, as measured in an ELISpot assay.

Graphic representation of the ELISpot assays A. cMCADs: patients with clonal mast cell activation disorders. Non-cMCAD control groups: MCAS: patients with idiopathic mast cell activation syndrome; CTR: non-cMCAD/non-MCAS control patients convalescing from COVID-19 (n=32). Empty circles: no history of COVID-19. Filled circles: history of COVID-19. **Pictures of ELISpot assays. B:** A well with non-stimulated PBMCs from a COVID-19 non-cMCAD control. **C**: A well with non-stimulated PBMCs from a COVID-19 cMCAD patient. **D**: A well with PBMCs from a COVID-19 non-cMCAD control after stimulation for 18-20 h with individual 15-mer 11-aa overlapping peptide pools derived from the SARS-CoV-2 N-terminal fragment spike protein. **E**: A well with PBMCs from a COVID-19 cMCAD patient after stimulation with individual 15-mer 11-aa overlapping peptide pools derived from the SARS-CoV-2 N-terminal fragment spike protein.




Figure 4: Correlation between basal tryptase level (μ g/L) and spontaneous IFN- γ production (spot-forming cells (SFCs)/2x10⁵ CD3), as observed in ELISpot assays. n=24 patients with CM, MIS and ISM. Linear regression: r²=0.44 (p=0.0004).